01—Abstract
Summary
Summary of the 8-K filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories (ABT) announced the upcoming retirement of its Executive Vice President, Finance, Robert E.
Funck, Jr., effective July 1, 2024. Mr. Funck's departure follows a distinguished 36-year career with the company. This transition marks the end of an era for a key financial executive, and investors will be keen to understand the succession plan and the impact on the company's financial leadership and strategy moving forward.
02—Key points
Key Highlights
- Retirement of Robert E. Funck, Jr., Executive Vice President, Finance, effective July 1, 2024.
- Mr. Funck has served Abbott Laboratories for 36 years.
- The event date for this change was April 25, 2024.
- The filing was made on April 30, 2024, with an event date of April 26, 2024 for the officer notification.
- This filing falls under Item 5.02 of Form 8-K, concerning director and officer changes.
- Philip P. Boudreau, Senior Vice President, Finance and Chief Financial Officer, signed the filing.
03—Questions
Frequently Asked Questions
Who is leaving Abbott Laboratories?
Robert E. Funck, Jr., Executive Vice President, Finance, is retiring from Abbott Laboratories.
When is Robert E. Funck, Jr.'s retirement effective?
His retirement is effective July 1, 2024.
How long has Robert E. Funck, Jr. been with Abbott Laboratories?
Mr. Funck has served the company for 36 years.
What is the significance of this announcement for investors?
This announcement signifies a change in key financial leadership. Investors will likely be looking for information regarding the succession plan for Mr. Funck's role and any potential impact on the company's financial strategy and execution.
04—Continue